New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors
详细信息 查看全文
- 作者：Ivan B. Yanachkova ; ivan.yanachkov@glsynthesis.com" class="auth_mail" title="E-mail the corresponding author ; Hung Changc ; d ; Milka I. Yanachkovaa ; Edward J. Dixa ; Michelle A. Berny-Langb ; Thomas Gremmelb ; Alan D. Michelsonb ; c ; George E. Wrighta ; Andrew L. Frelinger IIIb ; c
- 关键词：Antiplatelet therapy ; Antithrombotics ; Adenosine diphosphate ; Cardiovascular disease ; Acute coronary syndromes ; P2Y1 ; P2Y12 ; P2X1 ; Dinucleoside polyphosphates ; Bis-nucleoside polyphosphates ; Inhibitors ; Platelets
- 刊名：European Journal of Medicinal Chemistry
- 出版年：2016
- 出版时间：1 January 2016
- 年：2016
- 卷：107
- 期：Complete
- 页码：204-218
- 全文大小：1149 K
文摘
- •
Effect of Ap4A modification on human platelet aggregation and P2Y1 and P2Y12 receptor inhibition.
- •
SAR within Ap4A scaffold for platelet aggregation and P2Y1/P2Y12 inhibition was established.
- •
Some Ap4A derivatives potently and reversibly inhibit ADP induced human platelet aggregation.
- •
Some Ap4A derivatives synergistically inhibit both platelet P2Y1 and P2Y12 receptors.